<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1403</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2024</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>28</volume>
<number>5</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator</title>
	<subject_fa>Molecular Immunology &amp; Vaccines</subject_fa>
	<subject>Molecular Immunology &amp; Vaccines</subject>
	<content_type_fa>سیتماتیک ریویو</content_type_fa>
	<content_type>Systematic Review</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span calibri=&quot;&quot; style=&quot;font-family:&quot;&gt;C&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;himeric antigen receptor (CAR) T-cell therapy is a groundbreaking approach for treating certain hematologic malignancies and solid tumors. However, its application is limited by severe toxicities, particularly &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;span style=&quot;font-size:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span calibri=&quot;&quot;&gt;cytokine release syndrome&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span calibri=&quot;&quot;&gt; (CRS) and &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span calibri=&quot;&quot;&gt;cell-associated neurotoxicity syndrome&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:10.5pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span calibri=&quot;&quot;&gt; (ICANS), dramatically limit its broader application. IL-1 plays a crucial role in both enhancing CAR T-cell efficacy and driving these toxic effects. This review systematically examines the dual functions of IL-1, highlighting its role in promoting CAR T-cell activation and persistence while contributing to CRS and ICANS pathogenesis. Strategies to mitigate IL-1-driven toxicities, including IL-1 receptor antagonists, monoclonal antibodies, IL-1 trapping, and interference with IL-1 production, show promise in reducing adverse effects without compromising therapeutic efficacy. Understanding the complex role of IL-1 in CAR T-cell therapy may lead to optimized treatment strategies, improving safety and expanding clinical applicability. Further research is essential to refine IL-1-targeted interventions and enhance the therapeutic potential of CAR T-cell therapy. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&amp;nbsp;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Interleukin-1, cytokine release syndrome, Chimeric antigen receptor T cells</keyword>
	<start_page>221</start_page>
	<end_page>234</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1382-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Amirhosein</first_name>
	<middle_name></middle_name>
	<last_name>Maali</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>maali.amirhosein@gmail.com</email>
	<code></code>
	<orcid>0000-0002-0699-3010</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunology, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Ahmad</first_name>
	<middle_name></middle_name>
	<last_name>Noei</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ahmet.noei.pharm@gmail.com</email>
	<code></code>
	<orcid>0009-0009-3978-2402</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunology, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Saba</first_name>
	<middle_name></middle_name>
	<last_name>Feghhi-Najafabadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>sabafeghhi@gmail.com</email>
	<code></code>
	<orcid>0000-0002-3105-6475</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunology, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Zahra</first_name>
	<middle_name></middle_name>
	<last_name>Sharifzadeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>zsharifzadeh@gmail.com</email>
	<code></code>
	<orcid>0000-0002-4419-0315</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Immunology, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
